# **Table of Contents**

**State/Territory Name: Vermont** 

State Plan Amendment (SPA) #: 23-0013

This file contains the following documents in the order listed:

- 1) Approval Letter
- 2) CMS 179 Form/Summary Form (with 179-like data)
- 3) Approved SPA Pages

## DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-26-12 Baltimore, Maryland 21244-1850



May 3, 2023

Adaline Strumolo, Deputy Commissioner Department of Vermont Health Access (DVHA) NOB 1 South, 280 State Drive Waterbury, VT 05671-1010

Re: Vermont State Plan Amendment (SPA) 23-0013

## Dear Deputy Commissioner Strumolo:

The Centers for Medicare & Medicaid Services (CMS) reviewed the proposed Medicaid State Plan Amendment (SPA) and accompanying section 1135 waivers submitted on February 21, 2023 under transmittal number (TN) VT 23-0013. This amendment proposes to document Vermont's mandatory coverage of COVID-19 vaccine and administration, testing, and treatment benefits as required by section 9811 of the American Rescue Plan Act.

Pursuant to section 1135(b)(5) of the Social Security Act (Act), for the period of the public health emergency, CMS is modifying the requirement at 42 C.F.R. §430.20 that the state submit SPAs related to the COVID-19 public health emergency by the final day of the quarter, to obtain a SPA effective date during the quarter, enabling SPAs submitted after the last day of the quarter to have an effective date in a previous quarter, but no earlier than the effective date of the public health emergency.

The State of Vermont also requested a waiver to modify the public notice requirements applicable to the SPA submission process. Pursuant to section 1135(b)(5) of the Act, CMS is modifying public notice requirements applicable to the SPA submission process. Public notice for SPAs is required under 42 C.F.R. §447.205 for changes in statewide methods and standards for setting Medicaid payment rates, 42 C.F.R. §447.57 for changes to premiums and cost sharing, and 42 C.F.R. §440.386 for changes to Alternative Benefit Plans (ABPs). Pursuant to section 1135(b)(5) of the Act, CMS is approving the state's request to modify these notice requirements otherwise applicable to SPA submissions.

CMS conducted our review of your submittal according to statutory requirements in Title XIX of the Act and implementing regulations. This letter is to inform you that Vermont's Medicaid SPA Transmittal Number VT 23-0013 is approved effective March 11, 2021.

If you have any questions, please contact Gilson DaSilva at (617) 565-1227 or via email at Gilson.DaSilva@cms.hhs.gov.

Sincerely,

Alissa M. Digitally signed by Alissa M. Deboy -S Date: 2023.05.03 08:22:38 -04'00'

Alissa Mooney DeBoy On Behalf of Anne Marie Costello, Deputy Director Center for Medicaid and CHIP Services

Enclosures

Cc: Dylan Frazer, Deputy Director of Medicaid Policy

CENTERS FOR MEDICARE & MEDICAID SERVICES	OM DIV. 0930-0193		
TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES	2 3 — 0 0 1 3 VI		
TO: CENTER DIRECTOR CENTERS FOR MEDICAID & CHIP SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES	4. PROPOSED EFFECTIVE DATE  3/11/2021		
5. FEDERAL STATUTE/REGULATION CITATION  42 CFR §430.12(e)(1)(ii)  Section 9811 ARPA; 1905(a)(4)(E-F) of the SSA; Section 1135(b)(5) of the SSA	6. FEDERAL BUDGET IMPACT (Amounts in WHOLE dollars) a FFY 2022 \$ 0 b. FFY 2023 \$ 0		
7. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT Attachment 7.7-A, 7.7-B, 7.7-C	8. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION OR ATTACHMENT (If Applicable) N/A		
9. SUBJECT OF AMENDMENT			
Documenting Mandatory COVID Coverage - ARPA 9811			
10. GOVERNOR'S REVIEW (Check One)  GOVERNOR'S OFFICE REPORTED NO COMMENT COMMENTS OF GOVERNOR'S OFFICE ENCLOSED NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL	OTHER, AS SPECIFIED: Approval from Agency of Admin. or desig		
11. SIGNATURE OF STATE AGENCY OFFICIAL	15. RETURN TO  DYLAN FRAZER		
Jenney Samuelson	DEPARTMENT OF VERMONT HEALTH ACCESS		
13. TITLE SECRETARY, AGENCY OF HUMAN SERVICES	280 STATE DRIVE WATERBURY , VT 05671-1010		
14. DATE SUBMITTED 2/21/2023	DYLAN.FRAZER@VERMONT.GOV		
FOR CMS	USE ONLY		
16. DATE RECEIVED 02/21/2023	17. DATE APPROVED 05/03/2023		
PLAN APPROVED - O	NE COPY ATTACHED		
18. EFFECTIVE DATE OF APPROVED MATERIAL 03/11/2021	19. SIGNATURE OF APPROVING OFFICIAL Alissa M. Deboy -S De		
20. TYPED NAME OF APPROVING OFFICIAL Alissa Mooney DeBoy	21. TITLE OF APPROVING OFFICIAL On behalf of Anne Marie Costello, Deputy Director Center for Medicaid and CHIP Services		
22. REMARKS			
05/01/2023 - State provided P&I authority to revise the citations in	Box 5.		

### Vaccine and Vaccine Administration at Section 1905(a)(4)(E) of the Social Security Act

During the period starting March 11, 2021 and ending on the last day of the first calendar quarter that begins one year after the last day of the emergency period described in section 1135(g)(1)(B) of the Social Security Act (the Act):

<u>erage</u>	
X The state assures coverage of COVID-19 vaccines and administration of the vaccines. <sup>1</sup>	
X The state assures that such coverage:	
<ol> <li>Is provided to all eligibility groups covered by the state, including the optional Individuals Eligible for Family Planning Services, Individuals with Tuberculosis, and COVID-19 groups if applicable, with the exception of the Medicare Savings Program groups and the COBRA Continuation Coverage group for which medical assistance consists only of payment of premiums; and</li> <li>Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(H) and section 1916A(b)(3)(B)(xii) of the Act; reimbursement to qualified providers for such soverage is not reduced by any sect sharing that would otherwise be applied.</li> </ol>	-
such coverage is not reduced by any cost sharing that would otherwise be applicab under the state plan.	ie
X Applies to the state's approved Alternative Benefit Plans, without any deduction cost sharing or similar charge, pursuant to section 1937(b)(8)(A) of the Act.	,
_ XThe state provides coverage for any medically necessary COVID-19 vaccine counseling for children under the age of 21 pursuant to §§1902(a)(11), 1902(a)(43), and 1905(hh) of the Act.	
X The state assures compliance with the HHS COVID-19 PREP Act declarations and authorizations, including all of the amendments to the declaration, with respect to the provider that are considered qualified to prescribe, dispense, administer, deliver and/or distribute COVID-19 vaccines.	rs
Additional Information (Optional):	

TN No. <u>23-0013</u> Effective Date: <u>3/11/2021</u> Supersedes
TN No. <u>None</u> Approval Date: **05/03/2023** 

<sup>&</sup>lt;sup>1</sup> The vaccine will be claimed under this benefit once the federal government discontinues purchasing the vaccine.

## Reimbursement

The state assures that the state plan has established rates for COVID-19 vaccines and the administration of the vaccines for all qualified providers pursuant to sections 1905(a)(4)(E) and 1902(a)(30)(A) of the Act.
List Medicaid state plan references to payment methodologies that describe the rates for COVID-19 vaccines and their administration for each applicable Medicaid benefit:
_X The state is establishing rates for COVID-19 vaccines and the administration of the vaccines pursuant to sections 1905(a)(4)(E) and 1902(a)(30)(A) of the Act.
_X The state's rates for COVID-19 vaccines and the administration of the vaccines are consistent with Medicare rates for COVID-19 vaccines and the administration of the vaccines, including any future Medicare updates at the: X_ Medicare national average, OR Associated geographically adjusted rate.
The state is establishing a state specific fee schedule for COVID-19 vaccines and the administration of the vaccines pursuant to sections 1905(a)(4)(E) and 1902(a)(30)(A) of the Act.
The state's rate is as follows and the state's fee schedule is published in the following location:

\_\_X\_\_ The state's fee schedule is the same for all governmental and private providers.

TN No.\_23-0013 Supersedes TN No. None Effective Date: <u>3/11/2021</u>

Approval Date: <u>05/03/2023</u>

	The below listed providers are paid differently from the above rate schedules and payment to these providers for COVID-19 vaccines and the administration of the vaccines are described under the benefit payment methodology applicable to the provider type:
	The payment methodologies for COVID-19 vaccines and the administration of the vaccines for providers listed above are described below:
and	_XThe state is establishing rates for any medically necessary COVID-19 vaccine unseling for children under the age of 21 pursuant to sections 1905(a)(4)(E), 1905(r)(1)(B)(v) d 1902(a)(30)(A) of the Act.
_	cation:
	The reimbursement rate COVID-19 vaccine counseling for children under the age of 21 is 60% of billed charges.
	Fee schedule is published in the following location: <u>Vermont Medicaid Portal</u> ( <u>vtmedicaid.com</u> )

PRA Disclosure Statement Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The OMB control number for this project is 0938-1148 (CMS-10398 # 75). Public burden for all of the collection of information requirements under this control number is estimated to take up to 1 hour per response. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.

TN No.\_23-0013 Supersedes TN No. None Effective Date: <u>3/11/2021</u>

#### COVID-19 Testing at section 1905(a)(4)(F) of the Social Security Act

During the period starting March 11, 2021 and ending on the last day of the first calendar quarter that begins one year after the last day of the emergency period described in section 1135(g)(1)(B) of the Social Security Act (the Act):

#### <u>Coverage</u>

_X The state assures coverage of COVID-19 testing consistent with the Centers for Disease
Control and Prevention (CDC) definitions of diagnostic and screening testing for COVID-19 and
its recommendations for who should receive diagnostic and screening tests for COVID-19.

\_X\_\_ The state assures that such coverage:

- 1. Includes all types of FDA authorized COVID-19 tests;
- 2. Is provided to all categorically needy eligibility groups covered by the state that receive full Medicaid benefits;
- 3. Is provided to the optional COVID-19 group if applicable; and
- 4. Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(I) and 1916A(b)(3)(B)(xiii) of the Act; reimbursement to qualified providers for such coverage is not reduced by any cost sharing that would otherwise be applicable under the state plan.

Please describe any limits on amount, duration or scope of COVID-19 testing consistent with 42 CFR 440.230(b).

At-home COVID-19 antigen tests are limited to no more than 4 test kits (8 tests) every 30 days. Additional tests require prior authorization.

Non-preferred antigen tests require prior authorization.

_X	Applies to the sta	te's approved	Alternative	Benefit Plans,	without any	deduction,
cost s	haring, or similar	charge, pursua	ant to sectio	n 1937(b)(8)(E	3) of the Act.	ı

\_X\_\_The state assures compliance with the HHS COVID-19 PREP Act declarations and authorizations, including all of the amendments to the declaration.

TN No. <u>23-0013</u> Effective Date: <u>3/11/2021</u>

Supersedes TN No. None

#### Reimbursement

X The state assures that it has established state plan rates for COVID-19 testing consistent with the CDC definitions of diagnostic and screening testing for COVID-19 and its recommendations for who should receive diagnostic and screening tests for COVID-19. List references to Medicaid state plan payment methodologies that describe the rates for COVID-19 testing for each applicable Medicaid benefit: Inpatient Hospital Services Attachment 4.19-A Outpatient Hospital and Ambulatory Surgical Center Services Attachment 4.19-B Item 2a Rural Health Clinic Services/Federally Qualified Health Centers 4.19-B Item 2b Other Laboratory and X-Ray Services Attachment 4.19-B Item 3 Physician's Services Attachment 4.19-B Item 5 Clinic Services Attachment 4.19 B Item 9 Prescribed Drugs Attachment 4.19-B Item 12a (antigen tests) The state is establishing rates for COVID-19 testing pursuant to pursuant to sections 1905(a)(4)(F) and 1902(a)(30)(A) of the Act. The state's rates for COVID-19 testing are consistent with Medicare rates for testing, including any future Medicare updates at the: \_\_\_\_ Medicare national average, OR \_\_\_\_\_ Associated geographically adjusted rate. The state is establishing a state specific fee schedule for COVID-19 testing pursuant to sections 1905(a)(4)(F) and 1902(a)(30)(A) of the Act. The state's rate is as follows and the state's fee schedule is published in the following location:

The state's fee schedule is the same for all governmental and private providers.

TN No. <u>23-0013</u> Supersedes TN No. None Effective Date: \_3/11/2021\_

	The below listed providers are paid differently from the above rate schedules and payment to these providers for COVID-19 testing is described under the benefit payment methodology applicable to the provider type:
Addition	al Information (Optional):
- C	The payment methodologies for COVID-19 testing for providers listed above are described below:

PRA Disclosure Statement Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The OMB control number for this project is 0938-1148 (CMS-10398 # 75). Public burden for all of the collection of information requirements under this control number is estimated to take up to 1 hour per response. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.

TN No.\_23-0013 Supersedes TN No. None Effective Date: \_\_3/11/2021\_

## COVID-19 Treatment at section 1905(a)(4)(F) of the Social Security Act

During the period starting March 11, 2021 and ending on the last day of the first calendar quarter that begins one year after the last day of the emergency period described in section 1135(g)(1)(B) of the Social Security Act (the Act):

## **Coverage for the Treatment and Prevention of COVID**

_^ 1116 51	ate assures that such coverage:
	Includes any non-pharmacological item or service described in section 1905(a) of the Act, that is medically necessary for treatment of COVID-19; Includes any drug or biological that is approved (or licensed) by the U.S. Food &
	Drug Administration (FDA) or authorized by the FDA under an Emergency Use Authorization (EUA) to treat or prevent COVID-19, consistent with the applicable authorizations;
	Is provided without amount, duration or scope limitations that would otherwise apply when covered for purposes other than treatment or prevention of COVID-19;
	Is provided to all categorically needy eligibility groups covered by the state that receive full Medicaid benefits;
6.	Is provided to the optional COVID-19 group, if applicable; and Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(l) and 1916A(b)(3)(B)(xiii) of the Act; reimbursement to qualified providers for such coverage is not reduced by any cost sharing that would otherwise be applicable under the state plan.
	_ Applies to the state's approved Alternative Benefit Plans, without any deduction, t sharing, or similar charge, pursuant to section 1937(b)(8)(B) of the Act.
	ate assures compliance with the HHS COVID-19 PREP Act declarations and

TN No. <u>23-0013</u> Supersedes TN No. None

Effective Date: \_\_3/11/2021\_

### Coverage for a Condition that May Seriously Complicate the Treatment of COVID

_X_ The states assures coverage of treatment for a condition that may seriously complicate the treatment of COVID-19 during the period when a beneficiary is diagnosed with or is presumed to have COVID-19.
_X The state assures that such coverage:
<ol> <li>Includes items and services, including drugs, that were covered by the state as of March 11, 2021;</li> <li>Is provided without amount, duration or scope limitations that would otherwise apply when covered for other purposes;</li> <li>Is provided to all categorically needy eligibility groups covered by the state that receive full Medicaid benefits;</li> <li>Is provided to the optional COVID-19 group, if applicable; and</li> <li>Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(I) and 1916A(b)(3)(B)(xiii) of the Act; reimbursement to qualified providers for such coverage is not reduced by any cost sharing that would otherwise be applicable under the state plan.</li> </ol>
X_ Applies to the state's approved Alternative Benefit Plans, without any deduction, cost sharing, or similar charge, pursuant to section 1937(b)(8)(B) of the Act.
_XThe state assures compliance with the HHS COVID-19 PREP Act declarations and authorizations, including all of the amendments to the declaration.
Additional Information (Optional):
<u>Reimbursement</u> X The state assures that it has established state plan rates for COVID-19 treatment, including
specialized equipment and therapies (including preventive therapies).

List references to Medicaid state plan payment methodologies that describe the rates for COVID-19 treatment for each applicable Medicaid benefit:

TN No.\_23-0013 Supersedes TN No. None

Effective Date: <u>3/11/2021</u>

Rural Health Clinic Services/Federally Qualified Health Centers 4.19-B Item 2b Laboratory and X-Ray Services Attachment 4.19-B Item 3 Physician's Services Attachment 4.19-B Item 5 Clinic Services Attachment 4.19 B Item 9 Respiratory Care Attachment 4.19-B Item 22 Certified Pediatric and Family Nurse Practitioners Attachment 4.19-B Item 23 Resource-Based Relative Value Scale (RBRVS) Attachment 4.19-B Item 26 The state is establishing rates or fee schedule for COVID-19 treatment, including specialized equipment and therapies (including preventive therapies) pursuant to sections 1905(a)(4)(F) and 1902(a)(30)(A) of the Act. The state's rates or fee schedule is the same for all governmental and private providers. \_ The below listed providers are paid differently from the above rate schedules and payment to these providers for COVID-19 vaccines and the administration of the vaccines are described under the benefit payment methodology applicable to the provider type: Additional Information (Optional):

Outpatient Hospital and Ambulatory Surgical Center Services Attachment 4.19-B Item 2a

Prescribed Drugs Attachment 4.19-B Item 12a

Inpatient Hospital Services Attachment 4.19-A

Physician Administered Drugs Attachment 4.19-B Item 12 a

PRA Disclosure Statement Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The OMB control number for this project is 0938-1148 (CMS-10398 # 75). Public burden for all of the collection of information requirements under this control number is estimated to take up to 1 hour per response. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.

TN No. <u>23-0013</u> Effective Date: <u>3/11/2021</u> Supersedes

TN No. None Approval Date: 05/03/2023